(1) Department of Nephrology, Japanese Red Cross Narita Hospital, Narita, Chiba
(2) Department of Nephrology, Tokyo Medical University Ibaraki Medical Center, Ami, Ibaraki, Japan
(3) Department of Nephrology, University of Tsukuba, Tsukuba, Ibaraki, Japan
* Corresponding author Email: email@example.com
Antiglomerular basement membrane (anti-GBM) disease is a rare autoimmune disorder characterized by rapidly progressive glomerulonephritis (RPGN) with diffuse crescentic formation on renal biopsy, and it is a well-characterized cause of glomerulonephritis. Although the effectiveness of treatment using therapeutic plasma exchange combined with immunosuppressive agents to improve renal function has been reported, the prognosis for patients with this disease is poor. To improve the prognosis, it may be necessary to detect this disease in earlier stages and to treat it without delay. This critical review discusses the treatments and outcomes of anti-GBM disease.
Anti-GBM disease is rare, but the treatment has been reported to improve renal function. This disease needs to be detected in its early stages to tackle the life cycle of the disease.